Anthropic on October 27, 2026 published a progress update on its life sciences work, reporting early results from research partnerships with six drug development organizations — BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group — alongside its first in-house drug programs. The company said its strategy is to involve Claude across the drug development process, from target identification and molecule design to manufacturing…
This article has been indexed from Unite.AI
Read the original article:
Anthropic Reports Early Drug Development Progress With Claude